Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Capital Expenditures (2016 - 2025)

Tandem Diabetes Care (TNDM) has disclosed Capital Expenditures for 13 consecutive years, with -$9.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures rose 38.89% year-over-year to -$9.6 million, compared with a TTM value of $3.7 million through Dec 2025, up 623.87%, and an annual FY2025 reading of $3.7 million, up 623.87% over the prior year.
  • Capital Expenditures was -$9.6 million for Q4 2025 at Tandem Diabetes Care, down from $4.1 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $13.2 million in Q2 2022 and bottomed at -$15.7 million in Q4 2024.
  • Average Capital Expenditures over 5 years is $1.3 million, with a median of $3.8 million recorded in 2021.
  • The sharpest move saw Capital Expenditures surged 529.92% in 2022, then crashed 5529.86% in 2024.
  • Year by year, Capital Expenditures stood at $5.7 million in 2021, then tumbled by 101.43% to -$82000.0 in 2022, then plummeted by 239.02% to -$278000.0 in 2023, then plummeted by 5529.86% to -$15.7 million in 2024, then surged by 38.89% to -$9.6 million in 2025.
  • Business Quant data shows Capital Expenditures for TNDM at -$9.6 million in Q4 2025, $4.1 million in Q3 2025, and $6.2 million in Q2 2025.